title: Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
abstract: OBJECTIVE
  To investigate the efficacy and safety of adjuvant sorafenib after curative resection for patients with Barcelona Clinic Liver Cancer (BCLC)-stage C hepatocellular carcinoma (HCC).
  
  
  METHODS
  Thirty-four HCC patients, classified as BCLC-stage C, received adjuvant sorafenib for high-risk of tumor recurrence after curative hepatectomy at a tertiary care university hospital. The study group was compared with a case-matched control group of 68 patients who received curative hepatectomy for HCC during the study period in a 1:2 ratio.
  
  
  RESULTS
  The tumor recurrence rate was markedly lower in the sorafenib group (15/34, 44.1%) than in the control group (51/68, 75%, P = 0.002). The median disease-free survival was 12 mo in the study group and 10 mo in the control group. Tumor number more than 3, macrovascular invasion, hilar lymph nodes metastasis, and treatment with sorafenib were significant factors of disease-free survival by univariate analysis. Tumor number more than 3 and treatment with sorafenib were significant risk factors of disease-free survival by multivariate analysis in the Cox proportional hazards model. The disease-free survival and cumulative overall survival in the study group were significantly better than in the control group (P = 0.034 and 0.016, respectively).
  
  
  CONCLUSIONS
  Our study verifies the potential benefit and safety of adjuvant sorafenib for both decreasing HCC recurrence and extending disease-free and overall survival rates for patients with BCLC-stage C HCC after curative resection.
authors.affiliation: Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Xia
authors.affiliation: Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Wu
authors.affiliation: Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
authors.forename: Wan-Yee
authors.initials: WY
authors.lastname: Lau
authors.affiliation: Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
authors.forename: Hong-Bo
authors.initials: HB
authors.lastname: Huan
authors.affiliation: Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
authors.forename: Xu-Dong
authors.initials: XD
authors.lastname: Wen
authors.affiliation: Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
authors.forename: Kuan-Sheng
authors.initials: KS
authors.lastname: Ma
authors.affiliation: Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
authors.forename: Xiao-Wu
authors.initials: XW
authors.lastname: Li
authors.affiliation: Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Bie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009367:Neoplasm Staging; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors; D000077157:Sorafenib; D013030:Spain; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib
keywords: Hepatectomy; Hepatocellular carcinoma; Sorafenib; Survival; Tumor recurrence